Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

859
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
859
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Acute Pancreatitis I: Introduction01:25

Acute Pancreatitis I: Introduction

26
Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...
26
Cholecystitis01:20

Cholecystitis

32
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
32
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MMW Fortschritte der Medizin·2026
Same author

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
Same author

Nutritional Recommendations for the Prevention of Type 2 Diabetes Mellitus.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

MMW Fortschritte der Medizin·2026
Same author

Dietary recommendations for persons with type 2 diabetes mellitus.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

MMW Fortschritte der Medizin·2026

Related Experiment Video

Updated: May 6, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K

[Rare cause for severe hypertriglyceridemia - case 9/2013].

Sabine Kahl1, Michael Roden, Klaus Mörike

  • 1Klinik für Endokrinologie und Diabetologie, Universitätsklinikum Düsseldorf.

Deutsche Medizinische Wochenschrift (1946)
|November 14, 2013
PubMed
Summary

Tamoxifen treatment can cause severe hypertriglyceridemia, a serious lipid disorder. Patients with existing metabolic conditions require regular triglyceride monitoring during tamoxifen therapy.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Related Experiment Videos

Last Updated: May 6, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.7K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Tamoxifen is a widely used anti-estrogenic therapy for breast cancer.
  • Patients undergoing tamoxifen treatment may be at risk for metabolic complications.
  • Hypertriglyceridemia is a significant cardiovascular risk factor.

Observation:

  • A 48-year-old female patient developed severe hypertriglyceridemia after three months of tamoxifen therapy.
  • Laboratory results revealed hypertriglyceridemia, hypercholesterolemia, and decreased HDL-cholesterol.
  • The patient had a history of breast cancer treated with surgery and chemoradiotherapy.

Findings:

  • The observed hypertriglyceridemia was attributed to tamoxifen-induced drug effects.
  • Discontinuation of tamoxifen led to a consistent decrease in triglyceride levels.
  • No signs of pancreatitis were present, with normal serum amylase and lipase levels.

Implications:

  • Tamoxifen therapy necessitates regular monitoring of serum triglycerides, especially in patients with pre-existing dyslipidemia or type 2 diabetes.
  • Clinicians should consider tamoxifen as a potential cause of severe hypertriglyceridemia, even in rare cases.
  • This case highlights the importance of pharmacovigilance for metabolic side effects of endocrine therapies.